Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2025 Filed Mar 13, 2026 22:18 UTC |
Torres Erica MoniqueVP, Corporate Controller
|
Disposition to issuerOptions to Purchase · Derivative | 4 | $0.00 Strike: $1,125.00 | $0.00 |
DisclosureSEC source: 0001213900-26-027803 · ownership.xml · derivative · entry 4 Torres Erica Monique · CIK 0002113414 · VP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4 shares Expires 2033-10-01 F1 · derivative.exercise_price: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 5 have been adjusted to reflect the Reverse Stock Split. F5 · kind: On November 3, 2025, the stock options held by the reporting person were canceled by the issuer and new stock options were issued to the reporting person in exchange. F1 · shares: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 5 have been adjusted to reflect the Reverse Stock Split. F5 · shares: On November 3, 2025, the stock options held by the reporting person were canceled by the issuer and new stock options were issued to the reporting person in exchange. F4 · derivative.exercise_date: The options were subject to vesting commencing on October 2, 2023, with 1/4 of such shares having vested on October 2, 2024, and thereafter, 1/16 of such shares having vested or to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter. F1 · derivative.underlying_shares: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 5 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| December 31, 2025 Filed Mar 13, 2026 22:18 UTC |
Torres Erica MoniqueVP, Corporate Controller
|
Disposition to issuerOptions to Purchase · Derivative | 4 | $0.00 Strike: $1,125.00 | $0.00 |
DisclosureSEC source: 0001213900-26-027803 · ownership.xml · derivative · entry 3 Torres Erica Monique · CIK 0002113414 · VP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4 shares Expires 2033-02-23 F1 · derivative.exercise_price: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 5 have been adjusted to reflect the Reverse Stock Split. F5 · kind: On November 3, 2025, the stock options held by the reporting person were canceled by the issuer and new stock options were issued to the reporting person in exchange. F1 · shares: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 5 have been adjusted to reflect the Reverse Stock Split. F5 · shares: On November 3, 2025, the stock options held by the reporting person were canceled by the issuer and new stock options were issued to the reporting person in exchange. F3 · derivative.exercise_date: The options were subject to vesting commencing on February 24, 2023, with 1/4 of such shares having vested on February 24, 2024, and thereafter, 1/16 of such shares having vested or to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter. F1 · derivative.underlying_shares: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 5 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 16:05 UTC |
GUTIERREZ BARBARADirector
|
GrantOptions to Purchase · Derivative | 20,833 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001213900-25-113120 · ownership.xml · derivative · entry 1 GUTIERREZ BARBARA · CIK 0001846501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,833 Underlying: Common Stock · 20,833 shares Expires 2035-11-17 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ending December 31, 2025. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 16:05 UTC |
PETTITT JOHN PDirector
|
GrantOptions to Purchase · Derivative | 20,833 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001213900-25-113123 · ownership.xml · derivative · entry 1 PETTITT JOHN P · CIK 0001064145 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,833 Underlying: Common Stock · 20,833 shares Expires 2035-11-17 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ending December 31, 2025. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 16:05 UTC |
Schneider CarineDirector
|
GrantOptions to Purchase · Derivative | 20,833 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001213900-25-113122 · ownership.xml · derivative · entry 1 Schneider Carine · CIK 0001999633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,833 Underlying: Common Stock · 20,833 shares Expires 2035-11-17 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ending December 31, 2025. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 16:06 UTC |
Curtis Robert ArthurDirector
|
GrantOptions to Purchase · Derivative | 20,833 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001213900-25-113125 · ownership.xml · derivative · entry 1 Curtis Robert Arthur · CIK 0001424540 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,833 Underlying: Common Stock · 20,833 shares Expires 2035-11-17 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ending December 31, 2025. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:06 UTC |
Archer MarkChief Financial Officer
|
GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-106646 · ownership.xml · nonDerivative · entry 2 Archer Mark · CIK 0001913913 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By FLG Partners, LLC Disclosed balance after: 1,255 F1 · security: Issuable upon the vesting of a restricted stock award ("RSA"), each of which represents the right to receive one share of common stock, par value $0.0001 per share, of the issuer ("Common Stock"), subject to the vesting terms of such RSA. F2 · shares: The RSA of 25,000 shares of Common Stock was received as compensation for the reporting person's service as an officer pursuant to the issuer's 2023 Stock Incentive Plan. The RSA is subject to vesting commencing on November 3, 2025, with 1/4 of such shares to vest on November 3, 2026, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter. F3 · balance_after: On October 24, 2025, the issuer effected a one-for-seven hundred fifty reverse stock split of the issuer's outstanding shares of Common Stock (the "Reverse Stock Split"). The number of shares of Common Stock reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F4 · balance_after: The reporting person is a partner at FLG Partners, LLC, but disclaims beneficial ownership of such shares of Common Stock except to the extent of his pecuniary interest therein, and the inclusion of such shares of Common Stock in this report shall not be deemed an admission of beneficial ownership of all such reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:06 UTC |
Archer MarkChief Financial Officer
|
GrantCommon Stock | 23,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-106646 · ownership.xml · nonDerivative · entry 1 Archer Mark · CIK 0001913913 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,806 F1 · security: Issuable upon the vesting of a restricted stock award ("RSA"), each of which represents the right to receive one share of common stock, par value $0.0001 per share, of the issuer ("Common Stock"), subject to the vesting terms of such RSA. F2 · shares: The RSA of 25,000 shares of Common Stock was received as compensation for the reporting person's service as an officer pursuant to the issuer's 2023 Stock Incentive Plan. The RSA is subject to vesting commencing on November 3, 2025, with 1/4 of such shares to vest on November 3, 2026, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter. F3 · balance_after: On October 24, 2025, the issuer effected a one-for-seven hundred fifty reverse stock split of the issuer's outstanding shares of Common Stock (the "Reverse Stock Split"). The number of shares of Common Stock reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:05 UTC |
Simmons Chia-LinDirector · President and CEO
|
GrantCommon Stock | 74,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-106642 · ownership.xml · nonDerivative · entry 1 Simmons Chia-Lin · CIK 0001868194 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,967 F1 · security: Issuable upon the vesting of a restricted stock award ("RSA"), each of which represents the right to receive one share of common stock, par value $0.0001 per share, of the issuer ("Common Stock"), subject to the vesting terms of such RSA. F2 · shares: The RSA of 74,800 shares of Common Stock was received as compensation for the reporting person's service as an officer pursuant to the issuer's 2023 Stock Incentive Plan. The RSA is subject to vesting commencing on November 3, 2025, with 1/4 of such shares to vest on November 3, 2026, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter. F3 · balance_after: On October 24, 2025, the issuer effected a one-for-seven hundred fifty reverse stock split of the issuer's outstanding shares of Common Stock (the "Reverse Stock Split"). The number of shares of Common Stock reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| November 03, 2025 Filed Mar 13, 2026 22:18 UTC |
Torres Erica MoniqueVP, Corporate Controller
|
GrantOptions to Purchase · Derivative | 3,150 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001213900-26-027803 · ownership.xml · derivative · entry 6 Torres Erica Monique · CIK 0002113414 · VP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,150 Underlying: Common Stock · 3,150 shares Expires 2033-10-01 F1 · derivative.exercise_price: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 5 have been adjusted to reflect the Reverse Stock Split. F5 · kind: On November 3, 2025, the stock options held by the reporting person were canceled by the issuer and new stock options were issued to the reporting person in exchange. F1 · shares: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 5 have been adjusted to reflect the Reverse Stock Split. F5 · shares: On November 3, 2025, the stock options held by the reporting person were canceled by the issuer and new stock options were issued to the reporting person in exchange. F5 · price: On November 3, 2025, the stock options held by the reporting person were canceled by the issuer and new stock options were issued to the reporting person in exchange. F7 · price: The stock options were received as compensation for the reporting person's services as the issuer's Vice President, Corporate Controller. F8 · derivative.exercise_date: The options are subject to vesting which commenced on October 2, 2023, with 1/4 of such shares having vested on October 2, 2024, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter. F1 · derivative.underlying_shares: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 5 have been adjusted to reflect the Reverse Stock Split. F1 · balance_after: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 5 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| November 03, 2025 Filed Mar 13, 2026 22:18 UTC |
Torres Erica MoniqueVP, Corporate Controller
|
GrantOptions to Purchase · Derivative | 3,150 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001213900-26-027803 · ownership.xml · derivative · entry 5 Torres Erica Monique · CIK 0002113414 · VP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,150 Underlying: Common Stock · 3,150 shares Expires 2033-02-23 F1 · derivative.exercise_price: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 5 have been adjusted to reflect the Reverse Stock Split. F5 · kind: On November 3, 2025, the stock options held by the reporting person were canceled by the issuer and new stock options were issued to the reporting person in exchange. F1 · shares: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 5 have been adjusted to reflect the Reverse Stock Split. F5 · shares: On November 3, 2025, the stock options held by the reporting person were canceled by the issuer and new stock options were issued to the reporting person in exchange. F5 · price: On November 3, 2025, the stock options held by the reporting person were canceled by the issuer and new stock options were issued to the reporting person in exchange. F7 · price: The stock options were received as compensation for the reporting person's services as the issuer's Vice President, Corporate Controller. F6 · derivative.exercise_date: The options are subject to vesting which commenced on February 24, 2023, with 1/4 of such shares having vested on February 24, 2024, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter. F1 · derivative.underlying_shares: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 5 have been adjusted to reflect the Reverse Stock Split. F1 · balance_after: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 5 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| October 09, 2025 Filed Oct 14, 2025 16:40 UTC |
GUTIERREZ BARBARADirector
|
GrantOptions to Purchase · Derivative | 3,125,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-098797 · ownership.xml · derivative · entry 1 GUTIERREZ BARBARA · CIK 0001846501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,125,000 Underlying: Common Stock · 3,125,000 shares Expires 2035-10-08 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ended September 30, 2025. Read SEC document |
| October 09, 2025 Filed Oct 14, 2025 16:44 UTC |
PETTITT JOHN PDirector
|
GrantOptions to Purchase · Derivative | 3,125,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-098806 · ownership.xml · derivative · entry 1 PETTITT JOHN P · CIK 0001064145 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,125,000 Underlying: Common Stock · 3,125,000 shares Expires 2035-10-08 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ended September 30, 2025. Read SEC document |
| October 09, 2025 Filed Oct 14, 2025 16:42 UTC |
Schneider CarineDirector
|
GrantOptions to Purchase · Derivative | 3,125,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-098800 · ownership.xml · derivative · entry 1 Schneider Carine · CIK 0001999633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,125,000 Underlying: Common Stock · 3,125,000 shares Expires 2035-10-08 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ended September 30, 2025. Read SEC document |
| October 09, 2025 Filed Oct 14, 2025 16:43 UTC |
Curtis Robert ArthurDirector
|
GrantOptions to Purchase · Derivative | 3,125,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-098804 · ownership.xml · derivative · entry 1 Curtis Robert Arthur · CIK 0001424540 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,125,000 Underlying: Common Stock · 3,125,000 shares Expires 2035-10-08 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ended September 30, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 19:07 UTC |
GUTIERREZ BARBARADirector
|
GrantOptions to Purchase · Derivative | 2,500,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-061141 · ownership.xml · derivative · entry 1 GUTIERREZ BARBARA · CIK 0001846501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500,000 Underlying: Common Stock · 2,500,000 shares Expires 2035-06-30 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ended June 30, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 19:06 UTC |
PETTITT JOHN PDirector
|
GrantOptions to Purchase · Derivative | 2,500,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-061140 · ownership.xml · derivative · entry 1 PETTITT JOHN P · CIK 0001064145 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500,000 Underlying: Common Stock · 2,500,000 shares Expires 2035-06-30 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ended June 30, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 19:07 UTC |
Schneider CarineDirector
|
GrantOptions to Purchase · Derivative | 2,500,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-061144 · ownership.xml · derivative · entry 1 Schneider Carine · CIK 0001999633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500,000 Underlying: Common Stock · 2,500,000 shares Expires 2035-06-30 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ended June 30, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 19:07 UTC |
Curtis Robert ArthurDirector
|
GrantOptions to Purchase · Derivative | 2,500,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-061143 · ownership.xml · derivative · entry 1 Curtis Robert Arthur · CIK 0001424540 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500,000 Underlying: Common Stock · 2,500,000 shares Expires 2035-06-30 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ended June 30, 2025. Read SEC document |
| April 01, 2025 Filed Feb 5, 2026 16:34 UTC |
GUTIERREZ BARBARADirector
|
GrantOptions to Purchase · Derivative | 667 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001213900-26-012798 · ownership.xml · derivative · entry 1 GUTIERREZ BARBARA · CIK 0001846501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2035-03-31 F1 · derivative.exercise_price: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F1 · shares: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ending March 31, 2025. Read SEC document |
| April 01, 2025 Filed Feb 5, 2026 16:35 UTC |
PETTITT JOHN PDirector
|
GrantOptions to Purchase · Derivative | 667 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001213900-26-012800 · ownership.xml · derivative · entry 1 PETTITT JOHN P · CIK 0001064145 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2035-03-31 F1 · derivative.exercise_price: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F1 · shares: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ending March 31, 2025. Read SEC document |
| April 01, 2025 Filed Feb 5, 2026 16:35 UTC |
Schneider CarineDirector
|
GrantOptions to Purchase · Derivative | 667 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001213900-26-012802 · ownership.xml · derivative · entry 1 Schneider Carine · CIK 0001999633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2035-03-31 F1 · derivative.exercise_price: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F1 · shares: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ending March 31, 2025. Read SEC document |
| April 01, 2025 Filed Feb 5, 2026 16:34 UTC |
Curtis Robert ArthurDirector
|
GrantOptions to Purchase · Derivative | 667 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001213900-26-012799 · ownership.xml · derivative · entry 1 Curtis Robert Arthur · CIK 0001424540 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2035-03-31 F1 · derivative.exercise_price: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F1 · shares: On October 24, 2025, the issuer effected a 1-for-750 reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ending March 31, 2025. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 17:27 UTC |
GUTIERREZ BARBARADirector
|
GrantSeries A Common Stock Purchase Warrant · Derivative | 67,794 | $0.13 Strike: $0.12 | $8,474.25 |
DisclosureSEC source: 0001213900-25-026446 · ownership.xml · derivative · entry 1 GUTIERREZ BARBARA · CIK 0001846501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,742 Underlying: Common Stock · 67,794 shares Expires 2029-08-05 F1 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 17:29 UTC |
PETTITT JOHN PDirector
|
GrantSeries A Common Stock Purchase Warrant · Derivative | 67,794 | $0.13 Strike: $0.12 | $8,474.25 |
DisclosureSEC source: 0001213900-25-026454 · ownership.xml · derivative · entry 1 PETTITT JOHN P · CIK 0001064145 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,742 Underlying: Common Stock · 67,794 shares Expires 2029-08-05 F1 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 17:28 UTC |
Schneider CarineDirector
|
GrantSeries A Common Stock Purchase Warrant · Derivative | 67,794 | $0.13 Strike: $0.12 | $8,474.25 |
DisclosureSEC source: 0001213900-25-026450 · ownership.xml · derivative · entry 1 Schneider Carine · CIK 0001999633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,742 Underlying: Common Stock · 67,794 shares Expires 2029-08-05 F1 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 17:27 UTC |
Curtis Robert ArthurDirector
|
GrantSeries A Common Stock Purchase Warrant · Derivative | 67,794 | $0.13 Strike: $0.12 | $8,474.25 |
DisclosureSEC source: 0001213900-25-026442 · ownership.xml · derivative · entry 1 Curtis Robert Arthur · CIK 0001424540 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,742 Underlying: Common Stock · 67,794 shares Expires 2029-08-05 F1 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 21:29 UTC |
Archer MarkChief Financial Officer
|
GrantSeries A Common Stock Purchase Warrant · Derivative | 67,794 | $0.13 Strike: $0.12 | $8,474.25 |
DisclosureSEC source: 0001213900-25-026456 · ownership.xml · derivative · entry 1 Archer Mark · CIK 0001913913 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,742 Underlying: Common Stock · 67,794 shares Expires 2029-08-05 F1 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 21:29 UTC |
Simmons Chia-LinDirector · President and CEO
|
GrantSeries A Common Stock Purchase Warrant · Derivative | 67,794 | $0.13 Strike: $0.12 | $8,474.25 |
DisclosureSEC source: 0001213900-25-026452 · ownership.xml · derivative · entry 1 Simmons Chia-Lin · CIK 0001868194 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,742 Underlying: Common Stock · 67,794 shares Expires 2029-08-05 F1 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 16:08 UTC |
GUTIERREZ BARBARADirector
|
GrantSeries A Common Stock Purchase Warrant · Derivative | 11,238 | $0.13 Strike: $0.59 | $1,404.75 |
DisclosureSEC source: 0001213900-25-015675 · ownership.xml · derivative · entry 1 GUTIERREZ BARBARA · CIK 0001846501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,948 Underlying: Common Stock · 11,238 shares Expires 2029-08-05 F1 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 16:08 UTC |
PETTITT JOHN PDirector
|
GrantSeries A Common Stock Purchase Warrant · Derivative | 11,238 | $0.13 Strike: $0.59 | $1,404.75 |
DisclosureSEC source: 0001213900-25-015674 · ownership.xml · derivative · entry 1 PETTITT JOHN P · CIK 0001064145 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,948 Underlying: Common Stock · 11,238 shares Expires 2029-08-05 F1 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 16:08 UTC |
Schneider CarineDirector
|
GrantSeries A Common Stock Purchase Warrant · Derivative | 11,238 | $0.13 Strike: $0.59 | $1,404.75 |
DisclosureSEC source: 0001213900-25-015673 · ownership.xml · derivative · entry 1 Schneider Carine · CIK 0001999633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,948 Underlying: Common Stock · 11,238 shares Expires 2029-08-05 F1 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 16:07 UTC |
Curtis Robert ArthurDirector
|
GrantSeries A Common Stock Purchase Warrant · Derivative | 11,238 | $0.13 Strike: $0.59 | $1,404.75 |
DisclosureSEC source: 0001213900-25-015672 · ownership.xml · derivative · entry 1 Curtis Robert Arthur · CIK 0001424540 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,948 Underlying: Common Stock · 11,238 shares Expires 2029-08-05 F1 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:08 UTC |
Simmons Chia-LinDirector · President and CEO
|
GrantSeries A Common Stock Purchase Warrant · Derivative | 11,238 | $0.13 Strike: $0.59 | $1,404.75 |
DisclosureSEC source: 0001213900-25-015676 · ownership.xml · derivative · entry 1 Simmons Chia-Lin · CIK 0001868194 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,948 Underlying: Common Stock · 11,238 shares Expires 2029-08-05 F1 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:07 UTC |
Archer MarkChief Financial Officer
|
GrantSeries A Common Stock Purchase Warrant · Derivative | 11,238 | $0.13 Strike: $0.59 | $1,404.75 |
DisclosureSEC source: 0001213900-25-015671 · ownership.xml · derivative · entry 1 Archer Mark · CIK 0001913913 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,948 Underlying: Common Stock · 11,238 shares Expires 2029-08-05 F1 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. F1 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:55 UTC |
GUTIERREZ BARBARADirector
|
GrantOptions to Purchase · Derivative | 6,667 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001213900-25-001371 · ownership.xml · derivative · entry 1 GUTIERREZ BARBARA · CIK 0001846501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2035-01-01 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ended December 31, 2024, and have an exercise price of $1.50 per share, which was the closing price of the issuer's common stock, par value $0.0001 per share, on such date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:55 UTC |
PETTITT JOHN PDirector
|
GrantOptions to Purchase · Derivative | 6,667 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001213900-25-001373 · ownership.xml · derivative · entry 1 PETTITT JOHN P · CIK 0001064145 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2035-01-01 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ended December 31, 2024, and have an exercise price of $1.50 per share, which was the closing price of the issuer's common stock, par value $0.0001 per share, on such date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:55 UTC |
Schneider CarineDirector
|
GrantOptions to Purchase · Derivative | 6,667 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001213900-25-001374 · ownership.xml · derivative · entry 1 Schneider Carine · CIK 0001999633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2035-01-01 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ended December 31, 2024, and have an exercise price of $1.50 per share, which was the closing price of the issuer's common stock, par value $0.0001 per share, on such date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:54 UTC |
Curtis Robert ArthurDirector
|
GrantOptions to Purchase · Derivative | 6,667 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001213900-25-001370 · ownership.xml · derivative · entry 1 Curtis Robert Arthur · CIK 0001424540 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2035-01-01 F1 · shares: The stock options were received as compensation for the reporting person's services as a member of the board of directors of the issuer for the quarter ended December 31, 2024, and have an exercise price of $1.50 per share, which was the closing price of the issuer's common stock, par value $0.0001 per share, on such date. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 02:56 UTC |
Simmons Chia-LinDirector · President and CEO
|
GrantCommon Stock | 116,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-001376 · ownership.xml · nonDerivative · entry 1 Simmons Chia-Lin · CIK 0001868194 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,031 F1 · security: Issuable upon the vesting of a restricted stock award ("RSA"), each of which represents the right to receive one share of common stock, par value $0.0001 per share, of the issuer ("Common Stock"), subject to the vesting terms of such RSA. F2 · shares: The RSA of 116,900 shares of Common Stock was received as compensation for the reporting person's service as an officer pursuant to the issuer's 2023 Stock Incentive Plan. The RSA is subject to vesting commencing on January 2, 2025, with 1/4 of such shares to vest on January 2, 2026, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter. F3 · balance_after: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split of the issuer's outstanding shares of Common Stock (the "Reverse Stock Split"). The number of shares of Common Stock reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 02:55 UTC |
Archer MarkChief Financial Officer
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-001375 · ownership.xml · nonDerivative · entry 2 Archer Mark · CIK 0001913913 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By FLG Partners, LLC Disclosed balance after: 2,058 F2 · shares: The RSA of 40,000 shares of Common Stock was received as compensation for the reporting person's service as an officer pursuant to the issuer's 2023 Stock Incentive Plan. The RSA is subject to vesting commencing on January 2, 2025, with 1/4 of such shares to vest on January 2, 2026, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter. F3 · balance_after: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split of the issuer's outstanding shares of Common Stock (the "Reverse Stock Split"). The number of shares of Common Stock reported on this Form 4 have been adjusted to reflect the Reverse Stock Split and to increase the number of shares of Common Stock directly owned by the reporting person after such acquisition by 160 (on a post-Reverse Stock Split basis) in order to correct an administrative error in the Form 4 filed by the reporting person on August 6, 2024. F4 · balance_after: The reporting person is a partner at FLG but disclaims beneficial ownership of such shares of Common Stock except to the extent of his pecuniary interest therein, and the inclusion of such shares of Common Stock in this report shall not be deemed an admission of beneficial ownership of all such reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 02:55 UTC |
Archer MarkChief Financial Officer
|
GrantCommon Stock | 38,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-001375 · ownership.xml · nonDerivative · entry 1 Archer Mark · CIK 0001913913 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,955 F1 · security: Issuable upon the vesting of a restricted stock award ("RSA"), each of which represents the right to receive one share of common stock, par value $0.0001 per share, of the issuer ("Common Stock"), subject to the vesting terms of such RSA. F2 · shares: The RSA of 40,000 shares of Common Stock was received as compensation for the reporting person's service as an officer pursuant to the issuer's 2023 Stock Incentive Plan. The RSA is subject to vesting commencing on January 2, 2025, with 1/4 of such shares to vest on January 2, 2026, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter. F3 · balance_after: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split of the issuer's outstanding shares of Common Stock (the "Reverse Stock Split"). The number of shares of Common Stock reported on this Form 4 have been adjusted to reflect the Reverse Stock Split and to increase the number of shares of Common Stock directly owned by the reporting person after such acquisition by 160 (on a post-Reverse Stock Split basis) in order to correct an administrative error in the Form 4 filed by the reporting person on August 6, 2024. Read SEC document |
| December 17, 2024 Filed Feb 3, 2025 09:00 UTC |
Curtis Robert ArthurDirector
|
Disposition to issuerCommon Stock | 38 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-009143 · ownership.xml · nonDerivative · entry 1 Curtis Robert Arthur · CIK 0001424540 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 876 Read SEC document |
| November 26, 2024 Filed Nov 29, 2024 17:23 UTC |
GUTIERREZ BARBARADirector
|
GrantSeries B Common Stock Purchase Warrant · Derivative | 4,851 | $0.13 Strike: $1.75 | $606.38 |
DisclosureSEC source: 0001213900-24-104150 · ownership.xml · derivative · entry 2 GUTIERREZ BARBARA · CIK 0001846501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,710 Underlying: Common Stock · 4,851 shares Expires 2027-02-05 F1 · security: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · derivative.exercise_price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F2 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F1 · derivative.underlying_shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · balance_after: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. Read SEC document |
| November 26, 2024 Filed Nov 29, 2024 17:23 UTC |
GUTIERREZ BARBARADirector
|
GrantSeries A Common Stock Purchase Warrant · Derivative | 4,851 | $0.13 Strike: $1.75 | $606.38 |
DisclosureSEC source: 0001213900-24-104150 · ownership.xml · derivative · entry 1 GUTIERREZ BARBARA · CIK 0001846501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,710 Underlying: Common Stock · 4,851 shares Expires 2029-08-05 F1 · security: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · derivative.exercise_price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F2 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F1 · derivative.underlying_shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · balance_after: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. Read SEC document |
| November 26, 2024 Filed Nov 29, 2024 17:24 UTC |
PETTITT JOHN PDirector
|
GrantSeries B Common Stock Purchase Warrant · Derivative | 4,851 | $0.13 Strike: $1.75 | $606.38 |
DisclosureSEC source: 0001213900-24-104153 · ownership.xml · derivative · entry 2 PETTITT JOHN P · CIK 0001064145 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,710 Underlying: Common Stock · 4,851 shares Expires 2027-02-05 F1 · security: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · derivative.exercise_price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F2 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F1 · derivative.underlying_shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · balance_after: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. Read SEC document |
| November 26, 2024 Filed Nov 29, 2024 17:24 UTC |
PETTITT JOHN PDirector
|
GrantSeries A Common Stock Purchase Warrant · Derivative | 4,851 | $0.13 Strike: $1.75 | $606.38 |
DisclosureSEC source: 0001213900-24-104153 · ownership.xml · derivative · entry 1 PETTITT JOHN P · CIK 0001064145 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,710 Underlying: Common Stock · 4,851 shares Expires 2029-08-05 F1 · security: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · derivative.exercise_price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F2 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F1 · derivative.underlying_shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · balance_after: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. Read SEC document |
| November 26, 2024 Filed Nov 29, 2024 17:23 UTC |
Schneider CarineDirector
|
GrantSeries B Common Stock Purchase Warrant · Derivative | 4,851 | $0.13 Strike: $1.75 | $606.38 |
DisclosureSEC source: 0001213900-24-104151 · ownership.xml · derivative · entry 2 Schneider Carine · CIK 0001999633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,710 Underlying: Common Stock · 4,851 shares Expires 2027-02-05 F1 · security: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · derivative.exercise_price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F2 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F1 · derivative.underlying_shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · balance_after: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. Read SEC document |
| November 26, 2024 Filed Nov 29, 2024 17:23 UTC |
Schneider CarineDirector
|
GrantSeries A Common Stock Purchase Warrant · Derivative | 4,851 | $0.13 Strike: $1.75 | $606.38 |
DisclosureSEC source: 0001213900-24-104151 · ownership.xml · derivative · entry 1 Schneider Carine · CIK 0001999633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,710 Underlying: Common Stock · 4,851 shares Expires 2029-08-05 F1 · security: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · derivative.exercise_price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F2 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F1 · derivative.underlying_shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · balance_after: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. Read SEC document |
| November 26, 2024 Filed Nov 29, 2024 17:24 UTC |
Curtis Robert ArthurDirector
|
GrantSeries B Common Stock Purchase Warrant · Derivative | 4,851 | $0.13 Strike: $1.75 | $606.38 |
DisclosureSEC source: 0001213900-24-104156 · ownership.xml · derivative · entry 2 Curtis Robert Arthur · CIK 0001424540 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,710 Underlying: Common Stock · 4,851 shares Expires 2027-02-05 F1 · security: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · derivative.exercise_price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F2 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F1 · derivative.underlying_shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. F1 · balance_after: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.